Sangamo Therapeutics Announces Departure of Chief Monetary Officer Sung Lee
1 min readSangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic drugs organization, declared currently that Chief Financial Officer Sung Lee is leaving the Business to pursue a new option overseas. Mr. Lee’s final day of work will be February 1, 2021.
“Sung has contributed noticeably to Sangamo’s evolution, serving to us build a robust money situation to advance proprietary medicines for patients in require as we begin a year with quite a few opportunity catalysts,” claimed Sandy Macrae, Chief Government Officer of Sangamo. “I have deep appreciation for the integrity and management Sung brought to Sangamo. The administration crew and board of directors at Sangamo join me in wishing him the really very best as we initiate our search for a new CFO.”
“It has been a privilege to get the job done with Sandy and the Sangamo team to progress the progressive discipline of genomic medication, and I consider the business is very well positioned to execute on its system,” reported Mr. Lee.
About Sangamo Therapeutics
Sangamo Therapeutics is dedicated to translating ground-breaking science into genomic medicines with the likely to change patients’ life employing gene treatment, ex vivo gene-edited mobile remedy, and in vivo genome editing and genome regulation. For more info about Sangamo, check out www.sangamo.com.
Watch resource edition on businesswire.com: https://www.businesswire.com/information/residence/20210106005808/en/